Print This Post
As blood tests revolutionize Alzheimer’s diagnostics, healthcare providers need a straightforward way to assess which tools meet clinical standards. The Alzheimer’s Blood Test Performance Database from The Global CEO Initiative on Alzheimer’s Disease provides just that – a clear, centralized view of how each test compares against performance standards recommended by their expert BBM Workgroup.
This resource comes at a time of growing momentum in Alzheimer’s diagnostics—and growing urgency. Early and accurate diagnosis is essential to connecting patients with the right care, treatment, and support. But to achieve this, clinicians must have access to trustworthy, comparative insights about diagnostic tools. By equipping the field with this resource, CEOi strives to drive smarter decision-making, more confident clinical adoption, and ultimately, better outcomes for patients.
For more information and to access the CEOi Alzheimer’s Blood Test Performance Database, please visit the CEOi website.
Alz Forum
Alzheimer's Association